Pharmaxis Submits Investigational New Drug (IND) Application for the Treatment of Myelofibrosis

23rd Jul 20

Release Date: 23/07/2020 8:35am

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS), the leading developer of therapeutics targeting lysyl oxidase enzymes to treat fibrosis and cancer, announced it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for a planned phase 1/2 study of PXS-5505 for the treatment of myelofibrosis. The protocol incorporates a one-month dose escalation phase followed by 6 months’ treatment in an open label study of patients who are not on a JAK inhibitor.  The study is planned to commence in Q4 2020 and expected to conclude in 2022.

Read full media release - pdf

Categories: News and Media